Evidence map›Paper›PMID 32800200›Full record

ReviewClinics in chest medicine2020

Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks.

Takudzwa Mkorombindo, Mark T Dransfield

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in chest medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Mendelian causes of early-onset emphysema: a review of the current literature.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Treatment of lung diseasesMaterials today. Bio · 2025
    Review
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Nebulized corticosteroidsFrontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Takudzwa MkorombindoDivision of Pulmonary, Allergy and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, 1720 2nd Avenue South, THT 422, Birmingham, AL 35294-0006, USA.
Mark T DransfieldDivision of Pulmonary, Allergy and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, 526 20th Street South, Birmingham, AL 35294-0006, USA. Electronic address: mdransfield@uabmc.edu.
University of Alabama at Birmingham · US

Funding

UAB Mentoring Program in COPD Patient Oriented ResearchK24HL140108 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2018 to 2022
$439k
NHLBI NIH HHS K24 HL140108
6 · The paper itself

Abstract

Inhaled corticosteroids (ICSs), when used in combination with long-acting bronchodilators, reduce the risk of exacerbations and improve health-related quality of life in patients with chronic obstructive pulmonary disease (COPD) compared with bronchodilator or ICS therapy alone. Potential side effects of ICSs include adverse effects on glycemic control, bone density, cataract formation, skin changes, oral candidiasis, and pulmonary infections. Pneumonia is observed at increased rates in COPD patients, in particular those with greater airflow limitation, low body mass index, advanced age, and male gender, and ICSs may increase this risk. Risk assessment is essential in selecting appropriate patients for ICS-containing therapy.

Indexed as

Adrenal Cortex HormonesBronchodilator AgentsDrug Therapy, CombinationHumansPulmonary Disease, Chronic ObstructiveQuality of LifeRisk AssessmentAdrenal Cortex HormonesBronchodilator AgentsCOPDExacerbationsInhaled corticosteroidsPneumonia

Identifiers

PMID32800200
PMCPMC7521468
OpenAlexW3048513360

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.